GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS HealthBusiness Wire • 04/18/23
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion DealInvestors Business Daily • 04/18/23
Bellus Health's stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue missMarket Watch • 04/18/23
Best Dividend Stocks: British Pharma Giant GSK Boasts Attractive 5.2% YieldInvestors Business Daily • 04/12/23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to AdaptimmuneNewsfile Corp • 04/11/23
J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It OutInvestors Business Daily • 03/31/23
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alonePRNewsWire • 03/27/23